Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kelly Flagella"'
Autor:
Mathias Locher, Roy Forster, Wolfgang F. Richter, Frank-Peter Theil, Marque Todd, Kelly Flagella, Sven Kronenberg, Andreas Baumann, Lolke de Haan
Publikováno v:
Regulatory Toxicology and Pharmacology. 69:226-233
New challenges and opportunities in nonclinical safety testing of biologics were discussed at the 3rd European BioSafe Annual General Membership meeting in November 2013 in Berlin: (i)Approaches to refine use of non-human primates in non-clinical saf
Autor:
Jeffrey Eastham-Anderson, Mallika Singh, Xi Wang, Andrew Polson, Kelly Flagella, John A. Flygare, Sharon Yee, Bu Er Wang, Jo Anne Hongo, Shang Fan Yu, Melissa R. Junttila, Melissa Schutten, Rajesh Vij, David M. Goldenberg, Paul Polakis, Carter Fields, Thinh S Pham, Weiguang Mao, Ron Firestein
Publikováno v:
Science Translational Medicine. 7
Cancer stem cells (CSCs) are hypothesized to actively maintain tumors similarly to how their normal counterparts replenish differentiated cell types within tissues, making them an attractive therapeutic target for the treatment of cancer. Because mos
Autor:
Elaine Mai, Jay Tibbitts, Jagath Reddy Junutula, Reina N. Fuji, Hajime Hiraragi, Trung Nguyen, Mark X. Sliwkowski, Susan D. Spencer, Helga Raab, Richard A. Graham, Debra L. Dugger, Edward Ha, Kathryn Parsons, Paul Polakis, Gail Lewis Phillips, Richard H. Scheller, Guangmin Li, Kelly Flagella, Richard Vandlen, Sunil Bhakta
Publikováno v:
Clinical Cancer Research. 16:4769-4778
Purpose: Antibody drug conjugates (ADCs) combine the ideal properties of both antibodies and cytotoxic drugs by targeting potent drugs to the antigen-expressing tumor cells, thereby enhancing their antitumor activity. Successful ADC development for a
Autor:
Kevin McDorman, Michelle Simpson, Eileen T. Duenas, Carl Ng, Amy Kim, Siao Ping Tsai, Jihong Yang, Richard Vandlen, Helga Raab, Paul Polakis, William Mallet, Viswanatham Katta, Richard H. Scheller, Sunil Bhakta, Mark S. Dennis, Suzanna Clark, Henry B. Lowman, Yvonne Chen, Wai Lee Wong, Jeffrey Gorrell, Chien C Lee, Y Gloria Meng, Jagath Reddy Junutula, Yanmei Lu, Douglas D. Leipold, Sylvia Weir, Sarajane Ross, Kelly Flagella, Susan D. Spencer, Mark X. Sliwkowski, Rayna Venook
Publikováno v:
Nature Biotechnology. 26:925-932
Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs. However, conventional drug conjugation strategies yield heterogenous conjugates with relatively narrow therapeutic ind
Autor:
Camellia W. Adams, Kelly Flagella, Janet Clarke, David E. Allison, Noel Dybdal, Kathleen McKeever, Mark X. Sliwkowski, Leonard G. Presta
Publikováno v:
Cancer Immunology, Immunotherapy. 55:717-727
Dimerization is essential for activity of human epidermal growth factor receptors (HER1/EGFR, HER2/ErbB2, HER3/ErbB3, and ErbB4) and mediates intracellular signaling events leading to cancer cell proliferation, survival, and resistance to therapy. HE
Autor:
Kirsten Achilles Poon, Joo Hee Yi, Theresa Reynolds, Surinder Kaur, Joseph Beyer, Ola Saad, Noel Dybdal, Jay Tibbitts, Kelly Flagella, Sandhya Girish
Publikováno v:
Toxicology and applied pharmacology. 273(2)
Trastuzumab emtansine (T-DM1) is the first antibody-drug conjugate (ADC) approved for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The therapeutic premise of ADCs is based on the hypothesis that tar
Autor:
Boris Gorovits, Carmel M. Lynch, Diann Blanset, Garvin Warner, Kimberly Kramer-Stickland, Paul A. Andrews, Stanley A. Roberts, Kelly Flagella, Pauline L. Martin, Stephane Thibault
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 67(3)
Antibody drug conjugates (ADCs) include monoclonal antibodies that are linked to cytotoxic small molecules. A number of these agents are currently being developed as anti-cancer agents designed to improve the therapeutic index of the cytotoxin (i.e.,
Autor:
Helga Raab, Richard H. Scheller, Reina N. Fuji, Suzie J. Scales, Ola Saad, Darshana Ramesh Patel, Leslie A. Khawli, Willy Solis, Allen J. Ebens, Charles Eigenbrot, Dongwei Li, Janet Tien, Mark X. Sliwkowski, Elaine Mai, Luna Liu, Paul Polakis, Paul J. Mcdonald, Susan D. Spencer, Surinder Kaur, Shang-Fan Yu, Margaret Kenrick, Wai Lee Wong, Jay Tibbitts, Trung Nguyen, Philip E. Hass, Sunil Bhakta, Jakub Baudys, Richard Vandlen, Kelly Flagella, Jagath Reddy Junutula, Kathryn L Parsons-Reponte, Keyang Xu, Ben-Quan Shen
Publikováno v:
Nature biotechnology. 30(2)
The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of antibody conjugates. To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in sol
Autor:
Helga Raab, Kathryn Parsons, Mark X. Sliwkowski, Jagath Reddy Junutula, Kelly Flagella, Richard H. Scheller, Sunil Bhakta, Surinder Kaur, Luna Liu, Keyang Xu, Susan D. Spencer, Ben-Quan Shen, Paul Polakis
Publikováno v:
Cancer Research. 70:4396-4396
Antibody drug conjugates (ADCs) are attractive targeted chemo-therapeutic molecules as they combine ideal properties of both antibodies and cytotoxic drugs by targeting potent cytotoxic drugs to the antigen-expressing tumor cells, thereby enhancing t